Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
295 GBX | 0.00% | -5.75% | -16.31% |
02/04 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
02/04 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
Sales 2024 * | 34.22M 2.85B | Sales 2025 * | 45.52M 3.8B | Capitalization | 384M 32.02B |
---|---|---|---|---|---|
Net income 2024 * | -51M -4.25B | Net income 2025 * | -45M -3.75B | EV / Sales 2024 * | 6.17 x |
Net cash position 2024 * | 173M 14.42B | Net cash position 2025 * | 143M 11.9B | EV / Sales 2025 * | 5.3 x |
P/E ratio 2024 * |
-7.39
x | P/E ratio 2025 * |
-8.81
x | Employees | 143 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.02% |
Latest transcript on MaxCyte, Inc.
1 week | -5.75% | ||
Current month | -13.87% | ||
1 month | -14.49% | ||
3 months | -25.79% | ||
6 months | +21.65% | ||
Current year | -16.31% |
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 27/23/27 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 01/22/01 |
Art Mandell
BRD | Director/Board Member | 71 | 01/06/01 |
Will Brooke
BRD | Director/Board Member | 68 | 01/04/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.20% | 12 M€ | -.--% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 295 | 0.00% | 5,668 |
25/24/25 | 295 | -3.28% | 16,659 |
24/24/24 | 305 | -5.57% | 14,023 |
23/24/23 | 323 | +2.54% | 49,798 |
22/24/22 | 315 | +0.64% | 33,797 |
Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.31% | 384M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- MXCT Stock